IKT Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Inhibikase Therapeutics Inc

Watchlist Manager

Watchlist

Price: 2.28 USD 3.17% Market Closed

Market Cap: $301m

	Inhibikase Therapeutics Inc NASDAQ:IKT	US
	Philex Mining Corp F:0PX	PH
	HIVE Blockchain Technologies Ltd XTSX:HIVE	CA
S	Software AG OTC:SWDAF	DE
	Glass House Brands Inc NYSE:GLAS	US
M	Marks and Spencer Group PLC SWB:MA6	UK
	ESR-Logos REIT F:UZ0	SG
	Jungfraubahn Holding AG SIX:JFN	CH
	Wirecard AG OTC:WRCDF	DE
	City Developments Ltd F:CDE0	SG

Profitability Summary

Inhibikase Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Low Gross Margin

Low 3Y Average Gross Margin

Low Operating Margin

Negative 3Y Average Operating Margin

-11 950%

Low Net Margin

Negative 3Y Average Net Margin

-11 469%

Healthy Free Cash Flow Margin

Negative 3Y Average Free Cash Flow Margin

-10 304%

Negative ROE

-132%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-5 517%

Declining ROIC

-2 500% > -33 871%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.